-
1.发明授权Compositions and the use of interleukin-2 and/or interferon-beta and tumour necrosis factor for combination therapy or in providing medicaments or formulations 失效组合物和使用白介素-2和/或干扰素和肿瘤坏死因子进行联合治疗或提供药物或制剂
公开(公告)号：EP0248516B1
公开(公告)日：1991-07-24
申请号：EP87303120.7
申请日：1987-04-09
申请人： CETUS CORPORATION
CPC分类号： A61K38/2013 , A61K38/215 , A61K38/191 , A61K2300/00
-
2.发明公开Compositions and the use of interleukin-2 and/or interferon-beta and tumour necrosis factor for combination therapy or in providing medicaments or formulations 失效组合物和使用白介素-2和/或干扰素-β和肿瘤坏死因子的组合治疗或用于药物或制剂的制备。
公开(公告)号：EP0248516A1
公开(公告)日：1987-12-09
申请号：EP87303120.7
申请日：1987-04-09
申请人： CETUS CORPORATION
CPC分类号： A61K38/2013 , A61K38/215 , A61K38/191 , A61K2300/00
摘要： Anti-tumor activity in mammals can be augmented by administering to the mammalian host a synergistically effective amount of TNF and IL-2 or of TNF and IFN-β, or of TNF, IL-2 and IFN-β in combination. The composition of TNF and IL-2 and/or IFN-p may be prepared in vitro or administered separately to the host. If the TNF and IL-2 are administered sequentially, the TNF must be administered prior to the IL-2 to obtain synergy. The composition is useful for treating such cancers as mastocytoma, melanoma, leukemia, and lymphoma.
摘要翻译： 在哺乳动物中的抗肿瘤活性可以通过给予所述哺乳动物宿主协同有效量的TNF和IL-2的TNF或IFN和-β来增强，或TNF，IL-2和ITN的β组合。 TNF和IL-2和/或IFN-β的组合物可在体外制备或单独地施用给宿主。 如果TNF和IL-2被依次施用，所述TNF必须在IL-2之前给药以获得协同作用。 该组合物用于治疗如检查肥大细胞瘤，黑色素瘤，白血病，和淋巴瘤的癌症。
-
搜索结果
2 条记录 (耗时 0.007 秒)
